EUVIMEDEUVIMED entdecken
Crossref

Engineered Subcellular Transmembrane Protein Biomimetic Platform for In Situ Drug Discovery

Huifen Wu, Yanqiu Gu, Yanting Li, Shuya Jiang, Wei Dai, Haoran Wang, Kunmiao Feng, Dandan Guo, Dan Jia, Fei Cai, Yue Liu, Keyun Zeng und 6 weitere

Advanced Functional Materials · 2026-04 · 36 (32)

DOI: 10.1002/adfm.202530995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 07.01.2026. Verfasst von Huifen Wu und 17 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subcellular membrane environments pose major challenges to target‐oriented drug discovery due to the structural complexity and dynamic conformational transitions of transmembrane proteins. Conventional affinity chromatography techniques are limited by prolonged preparation period, lack of binding‐site resolution, and interference from endogenous membrane proteins. This study introduces i n situ synthesized t ransmembrane‐protein a ffinity chromatography (iSTAC), a biomimetic platform integrating cell‐free protein synthesis, engineered silica‐phase modification, and tethered lipid bilayers to reconstitute functional multipass transmembrane receptors under native‐like conditions. iSTAC enables the rapid column preparation within 5 h (a reduction in time of 33.6‐fold), while preserving structural integrity and conformational dynamics. This facilitates high‐specificity drug screening and binding‐site analysis. We used the 5 hydroxytryptamine receptor 1A (5‐HT 1A ) as a model to identify two natural agonists, crocin I and crocin II, from herbal extracts and validated their anti‐insomnia and neuroprotective effects in vivo. Mutational iSTAC analysis precisely mapped their binding interactions at the residues N386, T196, and S199, demonstrating that both compounds activate 5‐HT 1A via canonical signaling pathways.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, H., Gu, Y., Li, Y., Jiang, S., Dai, W., Wang, H., Feng, K., Guo, D., Jia, D., Cai, F., Liu, Y., Zeng, K., Lu, W., Dai, Y., Liu, W., Chen, Q., Han, T., & Chen, X. (2026). Engineered Subcellular Transmembrane Protein Biomimetic Platform for In Situ Drug Discovery. Advanced Functional Materials, 36(32). https://doi.org/10.1002/adfm.202530995

Vancouver

Wu H, Gu Y, Li Y, Jiang S, Dai W, Wang H, et al. Engineered Subcellular Transmembrane Protein Biomimetic Platform for In Situ Drug Discovery. Advanced Functional Materials. 2026;36(32). doi:10.1002/adfm.202530995

BibTeX
@article{Wu2026,
  author = {Wu, Huifen and Gu, Yanqiu and Li, Yanting and Jiang, Shuya and Dai, Wei and Wang, Haoran and Feng, Kunmiao and Guo, Dandan and Jia, Dan and Cai, Fei and Liu, Yue and Zeng, Keyun and Lu, Weilan and Dai, Yuanyuan and Liu, Wenyu and Chen, Qixin and Han, Ting and Chen, Xiaofei},
  title = {Engineered Subcellular Transmembrane Protein Biomimetic Platform for In Situ Drug Discovery},
  journal = {Advanced Functional Materials},
  year = {2026},
  volume = {36},
  number = {32},
  doi = {10.1002/adfm.202530995}
}
Kostenlos starten →